Controlled Trial of 3,4-Diaminopyridine (3-4DAP) in Lambert-Eaton Myasthenic Syndrome (LEMS)

NCT02090725 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

4

Enrollment

OTHER

Sponsor class

Stopped Drug receive FDA approval

Conditions

Muscle Weakness

Interventions

DRUG: 3-4 Diaminopyridine

Sponsor

Jeffrey A. Cohen, MD

Collaborators

[object Object]